Luque-Cabal et al., 2016 - Google Patents
Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome itLuque-Cabal et al., 2016
View HTML- Document ID
- 16303215565445851295
- Author
- Luque-Cabal M
- García-Teijido P
- Fernández-Pérez Y
- Sánchez-Lorenzo L
- Palacio-Vázquez I
- Publication year
- Publication venue
- Clinical Medicine Insights: Oncology
External Links
Snippet
The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The …
- 108010010691 Trastuzumab 0 title abstract description 134
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Luque-Cabal et al. | Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it | |
Pernas et al. | HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance | |
Majewski et al. | PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer | |
Iqbal et al. | Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications | |
Loree et al. | Recent developments in the treatment of metastatic colorectal cancer | |
Tagliabue et al. | HER2 as a target for breast cancer therapy | |
Millis et al. | Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors | |
Gavin et al. | Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2–positive breast cancer: analysis of the NSABP B-31 trial | |
Qu et al. | The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer | |
Mukohara | Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer | |
Fiszman et al. | Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer | |
Spector et al. | Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer | |
Crimini et al. | Precision medicine in breast cancer: From clinical trials to clinical practice | |
Nahta et al. | Trastuzumab: triumphs and tribulations | |
Nahta | Molecular mechanisms of trastuzumab‐based treatment in HER2‐overexpressing breast cancer | |
Zhang et al. | FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor–expressing metastatic colorectal cancer patients treated with single-agent cetuximab | |
Nahta et al. | HER-2-targeted therapy: lessons learned and future directions | |
Rimawi et al. | Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006 | |
Stern | Improving treatment of HER2-positive cancers: opportunities and challenges | |
Gunturu et al. | Gastric cancer and trastuzumab: first biologic therapy in gastric cancer | |
Hecht et al. | Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer | |
Tobin et al. | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer | |
Okines et al. | Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer | |
La Salvia et al. | HER2-targeted therapy: an emerging strategy in advanced colorectal cancer | |
Wahdan-Alaswad et al. | Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: Opportunities to overcome a difficult problem |